Community Protocol
NAD+
Preparation examples, syringe conversion, gradual community-reported patterns and evidence limitations.
Educational and calculation-reference material only. Community reports are uncontrolled anecdotes and do not replace professional medical guidance, product labeling, or individualized clinical monitoring.
Scope
Preparation examples, syringe conversion, gradual community-reported patterns and evidence limitations.
Available strengths: 500 MG and 1000 MG
Preparation Examples
These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.
| Setup | Diluent | Concentration | Unit conversion |
|---|---|---|---|
| 500 MG vial example | Add 2.5 mL bacteriostatic water | 200 mg/mL | Each U-100 unit = 2 mg |
| 1000 MG vial example | Add 5.0 mL if vial capacity allows | 200 mg/mL | Each U-100 unit = 2 mg |
Syringe Conversion
| Reported amount | 500 MG setup | 1000 MG setup |
|---|---|---|
| 20 mg | 10 units | 10 units |
| 40 mg | 20 units | 20 units |
| 60 mg | 30 units | 30 units |
| 100 mg | 50 units | 50 units |
Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.
Community-Reported Patterns
Anecdotal summary of the cited community discussions. These observations are descriptive, not a recommendation or evidence of safety or efficacy.
| Recurring report | Frequency seen | Context in reports |
|---|---|---|
| 20-40 mg | One to three times weekly | Lower-start reports |
| 40-100 mg | Two to three times weekly | Most recurring range |
| 100 mg or more | Intermittent in some reports | Higher experimental use |
Observations
- Community discussions most often centered on energy, mental clarity and recovery from fatigue.
- Gradual increases from 20 mg toward 100 mg appeared more often than beginning at the highest reported amount.
- The 500 MG and 1000 MG examples use the same concentration, so syringe conversion remains identical.
Caveats
- Direct human evidence for subcutaneous NAD+ schedules is limited, and community reports do not establish an appropriate dose or benefit.
- Vial capacity must be confirmed before adding 5 mL. If a different volume is used, the concentration and syringe conversion must be recalculated.